PubMed Daily Triage Digest — 2026-08-09

Run: 2026-08-09-attempt2-20260809T091558Z
CRDT window: 2026/08/08 – 2026/08/09
Indexed articles: 22 (12 HIGH · 10 MEDIUM)
Topics searched: 10 (9 with results; cbc_ml_hematology: 0 results)

🔴 HIGH Priority

T6 · Novel Therapeutics

[PMID 42571010] Pillozzi S et al. — The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026. J Hematol Oncol. 2026 Aug 8;19(1):53.
Score: 8 | open_access | human | Expert correspondence/Phase III summary

Phase III RASolute-302 trial: daraxonrasib (pan-RAS(ON) inhibitor) doubled median OS (13.2 vs. 6.6 months) vs. chemotherapy in 2nd-line mPDAC — new standard of care. Allele-specific G12D and G12C combinations also presented at ASCO 2026. 🏷️ phase_iii_data new_standard_of_care first_in_class

T7 · Cardiovascular-Metabolic

[PMID 42570467] Lin CH et al. — Risk of Dementia after initiation of GLP-1 RA versus long-acting insulin in patients with type 2 Diabetes mellitus. J Prev Alzheimers Dis. 2026 Aug 8;13(9):100645.
Score: 8 | abstract | human | Retrospective propensity-matched cohort (N=10,783 pairs)

GLP-1 RA associated with 36% lower dementia risk vs. long-acting insulin (HR 0.64, 95% CI 0.46–0.89); liraglutide (HR 0.40) and dulaglutide (HR 0.42) both protective for unspecified dementia in T2DM adults ≥50. 🏷️ glp1_neuroprotection real_world_evidence

T8 · Aging & Longevity

[PMID 42569826] Groeneveld J, van der Lee SJ et al. — APOE and genetic risk variants influence Alzheimer's disease onset in carriers of an extra copy of APP, with and without Down syndrome. Alzheimers Dement. 2026 Aug;22(8):e71738.
Score: 8 | abstract | human | Retrospective genetic cohort (APPdup N=100; DS N=957)

APOE ε2 delays AD onset (HR=0.47), APOE ε4 accelerates it (HR=1.5); combined APOE + polygenic AD-GRS explains 10-year span in predicted median AAO. Informs genetic counseling and trial stratification in autosomal dominant AD. 🏷️ alzheimers_genetics apoe_modifier down_syndrome

T5 · Precision Oncology

[PMID 42570981] Calukovic B, Deinzer CKW et al. — Durable clinical and immunologic response to an off-the-shelf EWSR1-FLI1 peptide vaccine in metastatic Ewing sarcoma. NPJ Precis Oncol. 2026 Aug 8;10(1):305.
Score: 7 | open_access | human | First-in-human case (n=1, longitudinal immune monitoring)

Off-the-shelf EWSR1-FLI1 fusion-derived peptide vaccine induced de novo polyfunctional CD4+ T-cell responses persisting >2 years and maintained disease stability >26 months. First-in-human proof of fusion-targeting precision immunotherapy in Ewing sarcoma. 🏷️ first_in_human cancer_vaccine fusion_oncology rare_pediatric_cancer

T1 · Hematologic Malignancies

[PMID 42570885] Elhusseiny K, Reeves BN. — The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting. Semin Hematol. 2026 Jul 17 (epub).
Score: 7 | abstract | human | Narrative review

All three MPN driver mutations (JAK2, CALR, MPL) converge on constitutive TPO/MPL signaling — unifying molecular hub for thromboinflammation, hemorrhage, and fibrotic progression. Emerging TPO/MPL-targeted strategies reviewed. 🏷️ mpn_pathogenesis tpo_mpl_axis

[PMID 42570342] Roos-Weil D. — Peripheral neuropathies associated with immunoglobulin M monoclonal gammopathies and low-grade B-cell lymphomas: diagnostic and therapeutic approach. Curr Opin Oncol. 2026 Sep 1;38(5):374-381.
Score: 7 | abstract | human | Narrative review

Anti-MAG neuropathy (most common IgM-associated neuropathy) and infiltrative/AL amyloidosis subtypes now treated with anti-CD20 and cBTKi; high-quality RCT evidence remains limited; persistent disability common. 🏷️ anti_mag_neuropathy btki

T4 · AI/ML Diagnostics

[PMID 42570951] Hahlbohm P, Löck S et al. — External validation of a top-ranked model from the RSNA pulmonary embolism detection challenge: assessment of generalizability. Sci Rep. 2026 Aug 8;16(1):24545.
Score: 7 | open_access | human | External validation study (N=1,038 CTPAs)

RSNA 2020 challenge 2nd-place DL model: AUROC 0.94 for any PE (sensitivity 0.80, specificity 0.97); central PE AUROC 0.99; SSPE AUROC only 0.48 — key gap for clinical deployment. 🏷️ deep_learning_validation pe_detection

T10 · Sentinel

[PMID 42571015] Trillo-Muyo S, Hansson GC et al. — A SNP altering the MUC5AC mucin structure is increased in idiopathic pulmonary fibrosis together with the MUC5B SNP. Respir Res. 2026 Jul 28;27(1):304.
Score: 7 | open_access | human | Genetic case-control (UK Biobank) + IHC

MUC5AC rs878913005 (stabilized mucin nets) 1.49x enriched in IPF (OR 2.09), in linkage disequilibrium with MUC5B risk SNP; both mucins accumulate in IPF honeycomb cysts. Rare disease, high unmet need. 🏷️ ipf_genetics rare_disease

[PMID 42571014] Lu AM, Bai SK et al. — TyG-VLR and incident CVD in CKM syndrome stages 0-3: longitudinal CHARLS analysis. Cardiovasc Diabetol. 2026 Jul 25;25(1):221.
Score: 7 | open_access | human | Prospective longitudinal cohort (N=7,132, 9-year follow-up)

Each 1-SD increase in baseline TyG-VLR: CVD HR 1.15, stroke HR 1.21 in CKM stages 0-3; repeated-measure burden: HR 1.21. Practical metabolic risk index for the new AHA CKM framework. 🏷️ ckm_syndrome metabolic_risk_index

T3 · Early Cancer Detection

[PMID 42570167] Al Srouji N, Puia IC et al. — Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer. Clin Transl Oncol. 2026 Aug 8 (epub).
Score: 7 | abstract | human | Comprehensive review

ctDNA MRD detection, fecal microbiome profiling (Fusobacterium nucleatum), and inflammatory immune indices converging toward 'Digital Twin' multimodal framework for personalized CRC adjuvant therapy. 🏷️ ctdna_mrd liquid_biopsy colorectal_cancer

T8 · Aging & Longevity (continued)

[PMID 42569366] Niu X, Zheng Y et al. — Immunosenescence shapes the tumor immune microenvironment and limits PD-1/PD-L1 blockade efficacy in older patients with cancer. Front Immunol. 2026 Jul 21;17:1781004.
Score: 7 | open_access | human | Narrative review

Thymic involution, reduced TCR diversity, SASP, and immunosuppressive cell expansion explain heterogeneous PD-1/PD-L1 benefit in elderly cancer patients; metabolic/microbiota targets proposed as modulators. 🏷️ immunosenescence checkpoint_blockade aging_oncology

T9 · Rare Diseases

[PMID 42570985] Alzahrani M et al. — Early-Onset Appendiceal Adenocarcinoma (Age <50): Temporal Trends, Histologic Patterns, and Survival from SEER 2000-2023. Ann Surg Oncol. 2026 Aug 8 (epub).
Score: 7 | abstract | human | Population registry analysis (SEER, N=10,452)

21.2% of appendiceal adenocarcinomas are early-onset; higher proportion Hispanic, mucinous histology, distant stage; survival driven by stage not age; racial disparities in non-Hispanic Black patients. 🏷️ rare_cancer racial_disparities

🟡 MEDIUM Priority

⚪ Topics With No Results

• cbc_ml_hematology — 0 results in CRDT window on both primary and fallback queries. No CBC/ML hematology articles indexed 2026-08-08 to 2026-08-09.

Coverage Summary

* 12 unique HIGH-priority articles in the JSON (42570981 and 42570167 are cross-listed in topic stats; each appears once in the articles array)

Key Signals for Pipeline

1. KRAS/mPDAC paradigm shift (PMID 42571010): Phase III RASolute-302 data establishes daraxonrasib as a new 2nd-line standard — highest priority for monitoring KRAS-mutant pancreatic cancer space.
2. GLP-1 RA neuroprotection (PMID 42570467): Large real-world cohort adds evidence for GLP-1 RA dementia prevention — monitor for RCT confirmation and NDA/regulatory movement.
3. AD genetic architecture in APP/DS (PMID 42569826): APOE/polygenic risk modifies onset by up to 10 years — directly relevant to precision AD prevention trial design.
4. Ewing sarcoma fusion vaccine (PMID 42570981): First-in-human data — monitor for expanded cohort trial announcement.
5. IPF/MUC5AC genetics (PMID 42571015): Sentinel find — new genetic risk factor in IPF expands beyond MUC5B; rare disease priority.